Jiuzhitang expects net profit attributable to the parent for the first half of 2026 to be between 241 million yuan and 264 million yuan, an increase of 67.63% to 83.63% from 144 million yuan in the same period last year. The profit growth is mainly due to the inclusion of Harbin Jixianglong Biotechnology in the consolidated financial statements in November 2025 and its sound operations, as well as the gradual results of the optimization of the main business segment structure and the reform of the marketing system, which boosted sales volumes for most products. Together with lean management and cost control measures, overall operating performance achieved growth.
Jiuzhitang Co LtdJiuzhitang expects net profit to rise 67.63%-83.63% due to consolidation of Harbin Jixianglong and operational improvements.
Harbin Jixianglong Biotechnology was consolidated into Jiuzhitang's financials and contributed to profit growth.